Indian Journal of Nuclear Medicine

CASE REPORT
Year
: 2013  |  Volume : 28  |  Issue : 1  |  Page : 28--29

Solitary sternal metastasis from hepatocellular carcinoma detected by F-18 FDG PET/CT


Koramadai Karuppusamy Kamaleshwaran, Raghava Kashyap, Anish Bhattacharya, Bhagwant Rai Mittal 
 Department of Nuclear Medicine and PET, Postgraduate Institute of Medical Education and Research, Chandigarh, India

Correspondence Address:
Bhagwant Rai Mittal
Department of Nuclear Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh - 160 012
India

Abstract

Fluorine-18 fluoro-deoxy-glucose positron emission tomography (F-18 FDG PET) is not sensitive modality for the diagnosis of primary hepatocellular carcinoma (HCC). However, FDG-PET imaging may be useful in the identification of extrahepatic metastases. We report an interesting image of HCC with solitary metastasis to sternum detected by F-18 FDG PET/CT.



How to cite this article:
Kamaleshwaran KK, Kashyap R, Bhattacharya A, Mittal BR. Solitary sternal metastasis from hepatocellular carcinoma detected by F-18 FDG PET/CT.Indian J Nucl Med 2013;28:28-29


How to cite this URL:
Kamaleshwaran KK, Kashyap R, Bhattacharya A, Mittal BR. Solitary sternal metastasis from hepatocellular carcinoma detected by F-18 FDG PET/CT. Indian J Nucl Med [serial online] 2013 [cited 2020 Aug 12 ];28:28-29
Available from: http://www.ijnm.in/text.asp?2013/28/1/28/116810


Full Text

 Introduction



Evaluation of primary hepatocellular carcinoma (HCC) using Fluorine-18 fluoro-deoxy-glucose positron emission tomography (F-18 (F-18 FDG PET) is not well-described. Extrahepatic metastases to the lung, lymph nodes, and bone are reported in up to 37% of HCC patients. [1],[2],[3] There is limited data on the role of F-18 FDG PET in the detection of metastasis from HCC. However, FDG-PET imaging has been reported to be an adjunct diagnostic modality in the identification of extrahepatic metastases from HCC, with a sensitivity of approximately 85%. [4],[5],[6] We report an interesting image of HCC with solitary metastasis to sternum detected by F-18 FDG PET/CT.

 Case Report



A 65-year-old male presented with pain abdomen, progressive deepening jaundice, weight loss of 15 kg and anorexia over last 6 months. Hepatitis B surface antigen was negative. Computed tomography (CT) scan of the abdomen in arterial phase showed a heterogeneously enhancing hypodense lesion in the left lobes and segment VIII of the right lobe of liver. Fine needle aspiration cytology (FNAC) was consistent with primary HCC. F-18 FDG PET/CT performed for visualizing the extent of tumor and metastatic work-up showed solitary sternal metastasis [Figure 1]. He was started on chemotherapy but later on died due to progression of the disease.{Figure 1}

 Discussion



The prognosis of patients with HCC is related to tumor stage at presentation and underlying liver function. Reliable staging of HCC is a fundamental precondition for deciding on the treatment modality and the Barcelona clinic liver cancer staging system links tumor stage with treatment modality. [7] In particular, accurate characterization of primary and metastatic HCC, showing the tendency toward early vascular invasion of the tumor is critical for proper treatment. [8] Imaging studies by dynamic CT and contrast-enhanced MRI are important in the diagnosis and staging of HCC, [7],[9],[10] but there is no consensus on which imaging tests are proper for detecting extrahepatic metastases.

F-18 FDG PET/CT might be useful in the evaluation of extrahepatic metastases. [4],[5],[6] Kawaoka et al. [4] compared the efficacy of PET/CT, multi-detector helical computed tomography (MDCT) and bone scintigraphy for the detection of extrahepatic metastases in patients with HCC. The mean sensitivity and specificity for diagnosis of lung metastasis from HCC were 85.2% and 88.9% for MDCT, and 59.2% and 92.6% for PET-CT, respectively. For lymph node metastases, these values were 62.5% and 79.2% for MDCT, and 66.7% and 91.7% for PET-CT, respectively; and for bone metastases 41.6% and 94.5% for MDCT, 83.3 and 86.1% for PET-CT. Because, whole-body combined PET/CT using F-18 FDG effectively detects numerous cancerous lesions this method is expected to improve the accuracy of HCC staging. [11] However, the high-level of glucose-6-phosphatase in liver tissue leads to the release of FDG-6-phosphate, resulting in reduced accumulation in differentiated HCCs. [12] This case highlights the usefulness of FDG PET/CT in detecting the solitary skeletal metastasis in HCC.

References

1Khan MA, Combs CS, Brunt EM, Lowe VJ, Wolverson MK, Solomon H, et al. Positron emission tomography scanning in the evaluation of hepatocellular carcinoma. J Hepatol 2000;32:792-7.
2Fukutomi M, Yokota M, Chuman H, Harada H, Zaitsu Y, Funakoshi A, et al. Increased incidence of bone metastases in hepatocellular carcinoma. Eur J Gastroenterol Hepatol 2001;13:1083-8.
3Horita K, Okazaki Y, Haraguchi A, Natsuaki M, Itoh T. A case of solitary sternal metastasis from unknown primary hepatocellular carcinoma. Nihon Kyobu Geka Gakkai Zasshi 1996;44:959-64.
4Kawaoka T, Aikata H, Takaki S, Uka K, Azakami T, Saneto H, et al. FDG positron emission tomography/computed tomography for the detection of extrahepatic metastases from hepatocellular carcinoma. Hepatol Res 2009;39:134-42.
5Ho CL, Chen S, Yeung DW, Cheng TK. Dual-tracer PET/CT imaging in evaluation of metastatic hepatocellular carcinoma. J Nucl Med 2007;48:902-9.
6Sugiyama M, Sakahara H, Torizuka T, Kanno T, Nakamura F, Futatsubashi M, et al. 18F-FDG PET in the detection of extrahepatic metastases from hepatocellular carcinoma. J Gastroenterol 2004;39:961-8.
7Bruix J, Sherman M, Practice Guidelines Committee. American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology 2005;42:1208-36.
8Jonas S, Bechstein WO, Steinmüller T, Herrmann M, Radke C, Berg T, et al. Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology 2001;33:1080-6.
9Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001;35:421-30.
10Park JW, An M, Choi JI, Kim YI, Kim SH, Lee WJ, et al. Accuracy of clinical criteria for the diagnosis of hepatocellular carcinoma without biopsy in a Hepatitis B virus-endemic area. J Cancer Res Clin Oncol 2007;133:937-43.
11Beyer T, Townsend DW, Brun T, Kinahan PE, Charron M, Roddy R, et al. A combined PET/CT scanner for clinical oncology. J Nucl Med 2000;41:1369-79.
12Ho CL, Yu SC, Yeung DW. 11C-acetate PET imaging in hepatocellular carcinoma and other liver masses. J Nucl Med 2003;44:213-21.